Literature DB >> 10665822

Striatal application of nicotine, but not of lobeline, attenuates dopamine release in freely moving rats.

D Lecca1, I Shim, E Costa, J I Javaid.   

Abstract

We investigated the physiological role of native low- and high-affinity nicotinic acetylcholine receptors (nAChRs) in regulating dopamine (DA) release from striatal DA terminals. To evaluate the functional interactions of the two receptor subtypes, nicotine (which interacts with both high- and low-affinity nAChRs) and lobeline (which selectively interacts with high-affinity nAChRs) were perfused through a microdialysis probe implanted into the striatum of freely moving rats. The DA content of successive dialysates was quantified by HPLC with an electrochemical detector. A short-lasting (1-min) perfusion of nicotine or lobeline dose-dependently increased the DA content of striatal dialysates. A second application of the same dose of nicotine resulted in an attenuated DA increase, compared with the increase elicited by the first application; however, the DA increase elicited by a second application of lobeline was similar to that of the first lobeline application. The nicotine-induced response was not attenuated when it followed a lobeline perfusion; in contrast, if the nicotine perfusion preceded that of lobeline, the lobeline-induced response was attenuated. In the presence of mecamylamine (a noncompetitive nAChR antagonist), the increase in DA content of striatal dialysate samples induced by either nicotine or lobeline was attenuated. However, in the presence of methyllycaconitine (a preferential antagonist for low-affinity alpha7 homomeric nAChRs), the nicotine response was attenuated but that of lobeline was unaffected. These results suggest that the functional inactivation of striatal nAChRs requires the simultaneous activation of both low- and high-affinity nAChRs. Since lobeline is devoid of reinforcing properties, one might infer that the reinforcing properties of nicotine require the simultaneous activation of high- and low-affinity brain nAChRs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665822     DOI: 10.1016/s0028-3908(99)00085-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

1.  The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs) after a protracted treatment with selective or nonselective nAChR agonists.

Authors:  J Auta; P Longone; A Guidotti; E Costa
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

2.  Differential effects of M1 muscarinic receptor blockade and nicotinic receptor blockade in the dorsomedial striatum on response reversal learning.

Authors:  Arianna Tzavos; Jane Jih; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2004-09-23       Impact factor: 3.332

Review 3.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

4.  In vivo effects of the anatoxin-a on striatal dopamine release.

Authors:  F Campos; R Durán; L Vidal; L R F Faro; M Alfonso
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

5.  Complex Control of Striatal Neurotransmission by Nicotinic Acetylcholine Receptors via Excitatory Inputs onto Medium Spiny Neurons.

Authors:  Valentina Licheri; Oona Lagström; Amir Lotfi; Mary H Patton; Holger Wigström; Brian Mathur; Louise Adermark
Journal:  J Neurosci       Date:  2018-06-25       Impact factor: 6.167

6.  The effects of lobeline and naltrexone on methamphetamine-induced place preference and striatal dopamine and serotonin levels in adolescent rats with a history of maternal separation.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-04       Impact factor: 3.584

7.  Ghrelin and nicotine stimulate equally the dopamine release in the rat amygdala.

Authors:  Miklós Palotai; Zsolt Bagosi; Miklós Jászberényi; Krisztina Csabafi; Roberta Dochnal; Máté Manczinger; Gyula Telegdy; Gyula Szabó
Journal:  Neurochem Res       Date:  2013-07-09       Impact factor: 3.996

8.  Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats.

Authors:  M N Lipovac; A Hashim; H Sershen; D Allen; T Cooper; P Czobor; A Lajtha
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

Review 9.  A neurochemical basis for an epigenetic vision of psychiatric disorders (1994-2009).

Authors:  Alessandro Guidotti; Dennis R Grayson
Journal:  Pharmacol Res       Date:  2011-06-15       Impact factor: 7.658

10.  The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes.

Authors:  S Rossi; S Singer; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.